Trials / Completed
CompletedNCT01639911
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.
Conditions
- Malignant Neoplasm of Breast
- CNS Malignancy
- Malignant Neoplasm of Gastrointestinal Tract
- Genitourinary Neoplasms Malignancy and Gender Unspecified
- Head and Neck Neoplasms
- Melanoma
- Malignant Neoplasm of Thorax
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alisertib | Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle. |
| DRUG | Pazopanib | Pazopanib at the assigned dose once a day continuously for the duration of treatment. |
Timeline
- Start date
- 2013-08-14
- Primary completion
- 2016-07-28
- Completion
- 2016-07-28
- First posted
- 2012-07-13
- Last updated
- 2019-07-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01639911. Inclusion in this directory is not an endorsement.